#1 Clinical Trials Search in Europe

Mk-6194

A new clinical trial is underway to investigate the potential of MK-6194 (also known as PT101) in treating active ulcerative colitis. This study aims to assess the safety, tolerability, and effectiveness of the drug when administered via subcutaneous injection. The trial will provide valuable insights into how MK-6194 interacts with the body and its potential impact on the immune system, particularly in patients with this inflammatory bowel condition.

Table of Contents

What is MK-6194?

MK-6194, also known as PT101, is a new medication being studied for the treatment of active ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease that affects the large intestine, causing symptoms like abdominal pain, diarrhea, and rectal bleeding[1]. This drug is currently undergoing clinical trials to evaluate its effectiveness and safety in patients with this condition.

Target Condition: Ulcerative Colitis

The primary focus of the MK-6194 study is on patients with active ulcerative colitis. This means that the researchers are specifically looking at how well the drug works in people who are currently experiencing symptoms of the disease, rather than those in remission[1].

Clinical Trial Details

The clinical trial for MK-6194 is a Phase 1b study, which means it’s an early-stage trial designed to gather initial data on the drug’s safety and effectiveness. Here are some key details about the trial:

  • It’s a randomized study, meaning participants are randomly assigned to either receive MK-6194 or a placebo (a substance that looks like the drug but has no active ingredients).
  • The study is double-blind, which means neither the participants nor the researchers know who is receiving the actual drug or the placebo. This helps to prevent bias in the results.
  • It’s a multicenter study, conducted at multiple medical facilities to gather data from a diverse group of patients.
  • The trial is designed to test multiple doses of MK-6194, with participants enrolled in sequential groups receiving increasingly higher doses of the drug[1].

How MK-6194 Works

While the exact mechanism of MK-6194 is not fully described in the available information, we can infer some details based on what the researchers are measuring:

  • The drug appears to affect certain types of immune cells, including regulatory T-cells (Tregs), natural killer (NK) cells, and conventional T cells (Tcons). These cells play important roles in the immune system and inflammation processes[1].
  • By influencing these immune cells, MK-6194 may help to reduce inflammation in the colon, potentially alleviating symptoms of ulcerative colitis.

Safety and Side Effects

A primary focus of this clinical trial is to evaluate the safety and tolerability of MK-6194. The researchers are closely monitoring:

  • The percentage of participants experiencing adverse events (AEs). An adverse event is any undesirable medical occurrence that happens during the study, whether or not it’s directly related to the drug[1].
  • The percentage of participants who have to stop taking the drug due to adverse events.

It’s important to note that all potential side effects are not yet known, as this is an early-stage trial designed to gather this information.

Drug Administration

MK-6194 is administered via subcutaneous injection. This means the drug is injected just under the skin, rather than into a vein or muscle. This method of administration is often preferred for drugs that need to be absorbed slowly and steadily into the bloodstream[1].

What Researchers Are Studying

The clinical trial is designed to gather a wide range of data about MK-6194. Here are some of the key aspects researchers are investigating:

  1. Pharmacokinetics: This refers to how the drug moves through the body. Researchers are measuring:
    • Maximum concentration (Cmax) of the drug in the blood
    • Time to reach maximum concentration (Tmax)
    • How long the drug stays in the body (half-life)
    • How quickly the body clears the drug (clearance)
    • How widely the drug distributes in the body (volume of distribution)[1]
  2. Pharmacodynamics: This refers to what the drug does to the body. Researchers are looking at:
    • Changes in the number of different types of immune cells in the blood
  3. Immunogenicity: This refers to whether the body develops an immune response to the drug itself. Researchers are measuring:
    • The presence and levels of anti-drug antibodies (ADAs)[1]

All of these measurements will help researchers understand how MK-6194 works in the body, how effective it might be for treating ulcerative colitis, and what side effects it might cause. This information is crucial for determining whether the drug should move forward to larger, more advanced clinical trials.

Aspect Details
Drug Name MK-6194 (also known as PT101)
Condition Studied Active Ulcerative Colitis
Administration Method Subcutaneous injection
Study Design Phase 1b, Randomized, Adaptive, Double-Blind, Placebo-Controlled, Multicenter
Primary Outcomes Percentage of participants experiencing adverse events and discontinuing treatment due to adverse events
Secondary Outcomes Pharmacokinetic parameters (Cmax, Tmax, AUC, etc.), changes in immune cell counts, anti-drug antibody titers
Study Duration Up to approximately 85 days

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (how the body processes the drug), pharmacodynamics (how the drug affects the body), and immunogenicity (immune system response) of MK-6194 in participants with active ulcerative colitis.
  • How is MK-6194 administered in this trial? MK-6194 is administered via subcutaneous injection, which means it's injected just under the skin.
  • What are the main outcomes being measured in this study? The main outcomes include the percentage of participants experiencing adverse events, the percentage discontinuing treatment due to adverse events, and various measurements of how the drug behaves in the body, such as its maximum concentration in the blood and how long it takes to reach that concentration.
  • Will the study look at how MK-6194 affects immune cells? Yes, the study will examine changes in the numbers of different types of immune cells, including regulatory T-cells (Tregs), Natural Killer (NK) cells, and conventional T cells (Tcons) in the blood.
  • How long will participants be monitored in this trial? Participants will be monitored for up to approximately 85 days, which is the timeframe for most of the study's measurements and observations.

Ongoing Clinical Trials on Mk-6194

  • Study on MK-6194 for Adults with Systemic Lupus Erythematosus

    Not recruiting

    1 1
    Investigated drugs:
    France Italy Poland Spain

  • Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany The Netherlands Spain

Glossary

  • Ulcerative Colitis (UC): A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract, primarily affecting the colon and rectum.
  • Pharmacokinetics: The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue just beneath the skin.
  • Adverse Event (AE): Any undesirable experience associated with the use of a medical product in a patient.
  • Maximum Concentration (Cmax): The highest concentration of a drug observed in the blood plasma after administration.
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time, calculated from a blood concentration-time graph.
  • Half-life: The time required for the concentration of a drug in the body to decrease by half.
  • Regulatory T-cells (Tregs): A type of immune cell that helps maintain balance in the immune system and prevent autoimmune diseases.
  • Natural Killer (NK) cells: A type of white blood cell that plays a major role in the body's immune defense against viruses and cancer cells.
  • Conventional T cells (Tcons): A type of immune cell that helps coordinate immune responses and can directly attack infected or abnormal cells.
  • Anti-drug antibody (ADA): Antibodies produced by the immune system in response to a therapeutic drug, which can potentially reduce the drug's effectiveness or cause side effects.

References

  1. https://clinicaltrials.gov/study/NCT04924114